Enhanced survival of dopaminergic neuronal transplants in hemiparkinsonian rats by the p53 inactivator PFT-α

Cell Transplantation

Volumn 20, Issue 9, 2011, Pages 1351-1359

  Chou, J ^a   Greig, N H ^b   Reiner, D ^a   Hoffer, B J ^a   Wang, Y ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b National Institute of Aging   (United States)

Author keywords

Apoptosis; Neuroprotection; P53; Parkinson's disease; Transplantation

Indexed keywords

PIFITHRIN ALPHA; PROTEIN P53; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CELL LABELING; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; FOREBRAIN; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MESENCEPHALON; NERVE FIBER GROWTH; NEURAL STEM CELL TRANSPLANTATION; NICK END LABELING; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; ROTATION; TREATMENT OUTCOME;

ANIMALS; BEHAVIOR, ANIMAL; BENZOTHIAZOLES; BRAIN TISSUE TRANSPLANTATION; CELL COUNT; CELL SURVIVAL; DOPAMINERGIC NEURONS; IN SITU NICK-END LABELING; MALE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TOLUENE; TUMOR SUPPRESSOR PROTEIN P53; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; PARKINSONIA; RATTUS;

EID: 80855129562     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368910X557173     Document Type: Article

References (29)

1. Biswas S. C.; Ryu E.; Park C.; Malagelada C.; Greene L. A. Puma and p53 play required roles in death evoked in a cellular model of Parkinson disease. Neurochem. Res. 30:839-845; 2005.
2. Borlongan C. V.; Su T. P.; Wang Y. Delta opioid peptide augments functional effects and intrastriatal graft survival of the fetal rat ventral mesencephalic cells. Cell Transplant. 10:53-58; 2001.
3. Chou J.; Harvey B. K.; Ebendal T.; Hoffer B. J.; Wang Y. Nigrostriatal alterations in bone morphogenetic protein receptor II dominant negative mice. Acta Neurochir. Suppl. 101:93-98; 2008.
4. Clarkson E. D.; Zawada W. M.; Freed C. R. GDNF improves survival and reduces apoptosis in human embryonic dopaminergic neurons in vitro. Cell Tissue Res. 289:207-210; 1997.
5. Culmsee C.; Zhu X.; Yu Q. S.; Chan S. L.; Camandola S.; Guo Z.; Greig N. H.; Mattson M. P. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J. Neurochem. 77:220-228; 2001.
6. Deng X.; Ladenheim B.; Tsao L. I.; Cadet J. L. Null mutation of c-fos causes exacerbation of methamphetamine-induced neurotoxicity. J. Neurosci. 19:10107-10115; 1999.
7. Duan W.; Zhu X.; Ladenheim B.; Yu Q. S.; Guo Z.; Oyler J.; Cutler R. G.; Cadet J. L.; Greig N. H.; Mattson M. P. P53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann. Neurol. 52:597-606; 2002.
8. Granholm A. C.; Mott J. L.; Bowenkamp K.; Eken S.; Henry S.; Hoffer B. J.; Lapchak P. A.; Palmer M. R.; van Horne C.; Gerhardt G. A. Glial cell line-derived neurotrophic factor improves survival of ventral mesencephalic grafts to the 6-hydroxydopamine lesioned striatum. Exp. Brain Res. 116:29-38; 1997.
9. Greig N. H. Drug entry to the brain and its pharmacological manipulation. In: Bradbury, M. W. B., ed. Handbook of experimental pharmacology. Heidelberg, Germany: Springer-Verlag; 1992:487-523.
10. Harvey B. K.; Chang C. F.; Chiang Y. H.; Bowers W. J.; Morales M.; Hoffer B. J.; Wang Y.; Federoff H. J. HSV amplicon delivery of glial cell line-derived neurotrophic factor is neuroprotective against ischemic injury. Exp. Neurol. 183:47-55; 2003.
11. Jeon B. S.; Jackson-Lewis V.; Burke R. E. 6-Hydroxydopamine lesion of the rat substantia nigra: Time course and morphology of cell death. Neurodegeneration 4:131-137; 1995.
12. Leker R. R.; Aharonowiz M.; Greig N. H.; Ovadia H. The role of p53-induced apoptosis in cerebral ischemia: Effects of the p53 inhibitor pifithrin alpha. Exp. Neurol. 187:478-486; 2004.
13. Liang Z. Q.; Li Y. L.; Zhao X. L.; Han R.; Wang X. X.; Wang Y.; Chase T. N.; Bennett M. C.; Qin Z. H. NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53. Brain Res. 1145:190-203; 2007.
14. Liu D. M.; Lin S. Z.; Wang S. D.; Wu M. I.; Wang Y. Xenografting human T2 sympathetic ganglion from hyperhidrotic patients partially restores catecholaminergic functions in hemi-parkinsonian athymic rats. Cell Transplant. 8:563-591; 1999.
15. Luo Y.; Hoffer B. J.; Wang Y. Rotation, drug-induced. In: Kompoliti, K.; Verhagen, L., eds. The encyclopedia of movement disorders (MOVE). London: Academic Press; 2010:49-51.
16. Luo Y.; Kuo C. C.; Shen H.; Chou J.; Greig N. H.; Hoffer B. J.; Wang Y. Delayed treatment with a p53 inhibitor enhances recovery in stroke brain. Ann. Neurol. 65:520-530; 2009.
17. Marchionini D. M.; Collier T. J.; Pitzer M. R.; Sortwell C. E. Reassessment of caspase inhibition to augment grafted dopamine neuron survival. Cell Transplant. 13:273-282; 2004.
18. Nair V. D. Activation of p53 signaling initiates apoptotic death in a cellular model of Parkinson's disease. Apoptosis 11:955-966; 2006.
19. Oo T. F.; Burke R. E. The time course of developmental cell death in phenotypically defined dopaminergic neurons of the substantia nigra. Brain Res. Dev. Brain Res. 98:191-196; 1997.
20. Schierle G. S.; Hansson O.; Leist M.; Nicotera P.; Widner H.; Brundin P. Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nat. Med. 5:97-100; 1999.
21. Sortwell C. E.; Pitzer M. R.; Collier T. J. Time course of apoptotic cell death within mesencephalic cell suspension grafts: Implications for improving grafted dopamine neuron survival. Exp. Neurol. 165:268-277; 2000.
22. Stromberg I.; Johnson S.; Hoffer B.; Olson L. Reinnervation of dopamine-denervated striatum by substantia nigra transplants: Immunohistochemical and electrophysiological correlates. Neuroscience 14:981-990; 1985.
23. Tang F. I.; Tien L. T.; Zhou F. C.; Hoffer B. J.; Wang Y. Intranigral ventromesencephalic grafts and nigrostriatal injection of GDNF restore dopamine release in the striatum of 6-OHDA-lesioned rats. Exp. Brain Res. 119:287-296; 1998.
24. Trimmer P. A.; Smith T. S.; Jung A. B.; Bennett, Jr. J. P. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration 5:233-239; 1996.
25. Wang Y.; Chang C. F.; Morales M.; Chiang Y. H.; Harvey B. K.; Su T. P.; Tsao L. I.; Chen S. Y.; Thiemermann C. Diadenosine tetraphosphate protects against injuries induced by ischemia and 6-hydroxydopamine in rat brain. J. Neurosci. 23:7958-7965; 2003.
26. Wang Y.; Tien L. T.; Lapchak P.; Hoffer B. J. GDNF triggers fiber outgrowth of fetal ventral mesencephalic grafts from nigra to striatum in 6-OHDA lesioned rats. Cell Tissue Res. 286:225-234; 1996.
27. Wang Y.; Wang S. D.; Lin S. Z.; Liu J. C. Restoration of dopamine overflow and clearance from the 6-hydroxydopamine lesioned rat striatum reinnervated by fetal mesencephalic grafts. J. Pharmacol. Exp. Ther. 270:814-821; 1994.
28. Yurek D. M.; Flectcher A. M.; Kowalczyk T. H.; Padegimas L.; Cooper M. J. Compacted DNA nanoparticle gene transfer of GDNF to the rat striatum enhances the survival of grafted fetal dopamine neurons. Cell Transplant. 18:1183-1196; 2009.
29. Zuch C. L.; Nordstroem V. K.; Briedrick L. A.; Hoernig G. R.; Granholm A. C.; Bickford P. C. Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion. J. Comp. Neurol. 427:440-454; 2000.